Last reviewed · How we verify
D-cure
D-cure is a therapeutic vaccine designed to stimulate the immune system to recognize and eliminate cancer cells expressing specific tumor-associated antigens.
D-cure is a therapeutic vaccine designed to stimulate the immune system to recognize and eliminate cancer cells expressing specific tumor-associated antigens. Used for Colorectal cancer, Other solid tumors (under investigation).
At a glance
| Generic name | D-cure |
|---|---|
| Also known as | license number: D-cure: 465S37F11 |
| Sponsor | KU Leuven |
| Drug class | Therapeutic cancer vaccine |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
D-cure works by activating dendritic cells and T-cell responses against tumor antigens, enabling the patient's own immune system to target and destroy cancer cells. The vaccine approach aims to generate durable anti-tumor immunity by priming both CD8+ and CD4+ T-cell responses. This personalized or off-the-shelf immunotherapy approach is intended to complement or enhance existing cancer treatments.
Approved indications
- Colorectal cancer
- Other solid tumors (under investigation)
Common side effects
- Injection site reactions
- Fatigue
- Fever
- Flu-like symptoms
Key clinical trials
- ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs (PHASE2)
- Adherence and Tolerability of Four Very Low-Calorie Ketogenic Diet Approaches in Adults With Obesity or Complicated Overweight
- Effects of Laser Therapy and Vitamin D Pills on Braces Tooth Movement: A Random Controlled Study (NA)
- SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC (PHASE2)
- A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer (PHASE2)
- Clinical Performances of 3-different Tooth-colored Restorative Materials in Class-II Cavities (NA)
- Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 (PHASE1)
- Comparison of Dendritic Cell-Based Therapeutic Vaccine Strategies for HIV Functional Cure (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- D-cure CI brief — competitive landscape report
- D-cure updates RSS · CI watch RSS
- KU Leuven portfolio CI